Goldman Sachs analyst Isaac Ro upgraded Quest Diagnostics to Conviction Buy and raised his six-month price target for the shares to $113 from $101. The company should be a key beneficiary as the U.S. healthcare system shifts the cost burden to the individual and creates price transparency for the first time, Ro tells investors in a research note. He believes Quest's ability to gain market share is not factored into consensus estimates.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

Quest Diagnostics announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease, supported by research as useful for an early diagnosis of AD. The test is the latest addition to the AD-Detect portfolio of blood tests for assessing the risk of Alzheimer's Disease, which also includes testing for an array of AD biomarkers, including p-tau181 and amyloid beta proteins, as well as Apolipoprotein E isoform and plasma testing, for patients with cognitive impairment. The test is expected to be available for ordering on April 26.